by Matthias Burel | Oct 25, 2023 | Clinical Trials
Rationale Sepsis is a life-threatening condition arising from a dysregulated immune response to infection, leading to tissue damage, organ failure, and potentially death. Delayed diagnosis significantly increases morbidity and mortality. The Global Burden of Disease...
by Matthias Burel | Oct 24, 2023 | Clinical Trials
Rationale Patients with haematological malignancies undergoing inpatient treatment, such as immunochemotherapy or stem cell transplantation, are at increased risk for rapid clinical deterioration. Complications like cytokine release syndrome (CRS) and immune effector...
by Matthias Burel | Oct 23, 2023 | Clinical Trials
Rationale Wearable devices are increasingly used to monitor physical activity in clinical and research settings, but their accuracy in children remains under-evaluated. The ActiGraph accelerometer is widely regarded as the gold standard for measuring physical activity...
by Matthias Burel | Oct 22, 2023 | Clinical Trials
Rationale Peak oxygen uptake (VO₂ max) is a key measure of cardiorespiratory fitness, yet its assessment typically requires maximal exertion testing with expensive equipment in a hospital setting. This limits routine monitoring and early detection of fitness-related...
by Matthias Burel | Oct 21, 2023 | Clinical Trials
Rationale Reliable heart rate (HR) monitoring in children is essential for both diagnostic and therapeutic monitoring in pediatric cardiology. Traditional 24-hour Holter ECGs remain the clinical gold standard but are often perceived as bulky, uncomfortable, and...
by Matthias Burel | Oct 20, 2023 | Clinical Trials
Rationale Targeted therapies such as osimertinib and alectinib, used to treat EGFR- and ALK-mutated non-small cell lung cancer (NSCLC), have substantially improved patient outcomes. However, both are known to cause cardiotoxic effects, including QTc prolongation and...
